Arrowhead Pharma (ARWR) Reiterated at Overweight by Cantor Fitzgerald

January 7, 2026 7:45 AM EST Send to a Friend
Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating and {REMOVEPT} price target on Arrowhead Pharma (NASDAQ: ARWR).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login